Sero-388 «2026 Edition»

One subject, a mother of two, described it as: “I know I love my children. I know what love felt like. But right now, it’s just data. I would jump in front of a train for them—not because I want to, but because my memory of myself says that’s what I would have done. So I do it. Mechanically. Perfectly. And I feel nothing.”

For three hours, Elias existed as pure phenomenal consciousness—sight, sound, proprioception, all streaming without an owner. He reported no fear. Not because he was brave, but because fear requires a self to be threatened. There was no self to protect.

Not thought suppression. Not meditation. Cessation. sero-388

SERO-388 was never meant for human trials. It was synthesized in 2038 (or 2041, depending on which leaked dataset you trust) as a selective inverse agonist of the 5-HT₂A receptor—but with a peculiar secondary affinity for the default mode network’s glutamatergic pacemaker cells. In lay terms, it doesn’t just alter consciousness. It performs a precise, reversible surgical ablation of the narrative self.

Pressed further, he said: “There is feeling. There is no one who feels it. There is memory of an Elias. But that memory is like a photograph of a stranger. I have no more emotional bond to his childhood than to a rock’s geology.” One subject, a mother of two, described it

He paused for nineteen seconds. Then: “That question has no referent.”

Most users return to baseline within six hours. But a significant subset—approximately 7.4% in the leaked Phase Ib data—develop what clinicians now call . They wake up the next day and the narrative self does not reboot. It’s not that they’ve lost memories. They remember their name, their history, their attachments. But those memories feel as compelling as a grocery list from a decade ago. The emotional gravity of being them never returns. I would jump in front of a train

The problem with SERO-388 is not the trip. It is the landing.